{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:29:42Z","timestamp":1792168182786,"version":"4.4.0"},"reference-count":22,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To compare the efficacy and safety of glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus (GDM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>In this prospective randomized controlled study, we randomly assigned patients with GDM at 13\u201333 weeks gestation and whose blood glucose was poorly controlled by diet to receive either glyburide or metformin. If optimal glycemic control was not achieved, the other drug was added. If adverse effects occurred, the drug was replaced. If both failed, insulin was given. The primary outcomes were the rate of treatment failure and glycemic control after the first-line medication according to mean daily glucose charts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Glyburide was started in 53 patients and metformin in 51. In the glyburide group, the drug failed in 18 (34%) patients due to adverse effects (hypoglycemia) in 6 (11%) and lack of glycemic control in 12 (23%). In the metformin group, the drug failed in 15 (29%) patients, due to adverse effects (gastrointestinal) in 1 (2%) and lack of glycemic control in 14 (28%). Treatment success after second-line therapy was higher in the metformin group than in the glyburide group (13 of 15 [87%] vs. 9 of 18 [50%], respectively; P = 0.03). In the glyburide group, nine (17%) patients were eventually treated with insulin compared with two (4%) in the metformin group (P = 0.03). The combination of the drugs reduced the need for insulin from 33 (32%) to 11 (11%) patients (P = 0.0002). Mean daily blood glucose and other obstetrical and neonatal outcomes were comparable between groups, including macrosomia, neonatal hypoglycemia, and electrolyte imbalance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Glyburide and metformin are comparable oral treatments for GDM regarding glucose control and adverse effects. Their combination demonstrates a high efficacy rate with a significantly reduced need for insulin, with a possible advantage for metformin over glyburide as first-line therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-2307","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T02:10:31Z","timestamp":1484187031000},"page":"332-337","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":83,"title":["Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study"],"prefix":"10.2337","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct01563120","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zohar","family":"Nachum","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Zafran","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Salim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Hissin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hasanein","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Emek Medical Center, Afula, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifat","family":"Gam Ze Letova","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Suleiman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enav","family":"Yefet","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"2022031301514018500_B1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM200010193431601","article-title":"A comparison of glyburide and insulin in women with gestational diabetes mellitus","volume":"343","author":"Langer","year":"2000","journal-title":"N Engl J Med"},{"key":"2022031301514018500_B2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"Metformin versus insulin for the treatment of gestational diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031301514018500_B3","doi-asserted-by":"crossref","first-page":"h102","DOI":"10.1136\/bmj.h102","article-title":"Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis","volume":"350","author":"Balsells","year":"2015","journal-title":"BMJ"},{"key":"2022031301514018500_B4","doi-asserted-by":"crossref","first-page":"457.e1","DOI":"10.1016\/j.ajog.2010.06.044","article-title":"Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis","volume":"203","author":"Dhulkotia","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"2022031301514018500_B5","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc07-s225","article-title":"Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus","volume":"30","author":"Metzger","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031301514018500_B6"},{"key":"2022031301514018500_B7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01.AOG.0000433006.09219.f1","article-title":"Practice bulletin no. 137: gestational diabetes mellitus","volume":"122","author":"Committee on Practice Bulletins\u2013Obstetrics","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2022031301514018500_B8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/AOG.0000000000000285","article-title":"Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011","volume":"123","author":"Camelo Castillo","year":"2014","journal-title":"Obstet Gynecol"},{"key":"2022031301514018500_B9","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ajog.2004.02.032","article-title":"Glyburide for the treatment of gestational diabetes","volume":"190","author":"Kremer","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"2022031301514018500_B10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijgo.2010.04.028","article-title":"Metformin compared with glyburide for the management of gestational diabetes","volume":"111","author":"Silva","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"2022031301514018500_B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/AOG.0b013e3181c52132","article-title":"Metformin compared with glyburide in gestational diabetes: a randomized controlled trial","volume":"115","author":"Moore","year":"2010","journal-title":"Obstet Gynecol"},{"key":"2022031301514018500_B12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/ajo.12276","article-title":"Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide\u2014a randomised controlled trial","volume":"55","author":"George","year":"2015","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2022031301514018500_B13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamapediatrics.2015.74","article-title":"Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes","volume":"169","author":"Camelo Castillo","year":"2015","journal-title":"JAMA Pediatr"},{"key":"2022031301514018500_B14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1210\/jc.2014-4403","article-title":"Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials","volume":"100","author":"Jiang","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301514018500_B15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0002-9378(82)90349-0","article-title":"Criteria for screening tests for gestational diabetes","volume":"144","author":"Carpenter","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"2022031301514018500_B16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diab.28.12.1039","article-title":"Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance","volume":"28","author":"National Diabetes Data Group","year":"1979","journal-title":"Diabetes"},{"key":"2022031301514018500_B17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ajog.2004.01.055","article-title":"The postprandial glucose profile in the diabetic pregnancy","volume":"191","author":"Ben-Haroush","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"2022031301514018500_B18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0261-3794(99)00028-1","article-title":"Loess: a nonparametric, graphical tool for depicting relationships between variables","volume":"19","author":"Jacoby","year":"2000","journal-title":"Elect Stud"},{"key":"2022031301514018500_B19","doi-asserted-by":"crossref","first-page":"e109985","DOI":"10.1371\/journal.pone.0109985","article-title":"Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: a meta-analysis","volume":"9","author":"Poolsup","year":"2014","journal-title":"PLoS One"},{"key":"2022031301514018500_B20","first-page":"308","article-title":"Glyburide for the treatment of gestational diabetes mellitus","volume":"60","author":"Kimber-Trojnar","year":"2008","journal-title":"Pharmacol Rep"},{"key":"2022031301514018500_B21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/AOG.0000000000000672","article-title":"Glyburide transport across the human placenta","volume":"125","author":"Schwartz","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2022031301514018500_B22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/clpt.2009.5","article-title":"Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice","volume":"85","author":"Hebert","year":"2009","journal-title":"Clin Pharmacol Ther"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/3\/332\/548263\/dc162307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/3\/332\/548263\/dc162307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:54:42Z","timestamp":1647150882000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/3\/332\/36967\/Glyburide-Versus-Metformin-and-Their-Combination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,1,11]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-2307","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}